upadacitinib (Rinvoq) Report issue

Active Ingredient History

  • Now
Upadacitinib (ABT-494) is a Janus kinase 1 (JAK1) inhibitor currently being developed by AbbVie for the treatment of rheumatoid arthritis (RA), Crohn’s disease, ulcerative colitis, atopic dermatitis, and psoriatic arthritis. It is also being investigated as a potential treatment for people with active ankylosing spondylitis (AS). Currently, upadacitinib is being evaluatedin six global phase III studies in RA and twophase III studies in psoriatic arthritis (PsA), inaddition to phase II studies in Crohn’s disease and atopicdermatitis and a combined phase II/III study inulcerative colitis. Upadacitinib is a potent and selective Janus kinase (JAK) 1 inhibitor with an IC50 of 43 nM.   NCATS

  • SMILES: CC[C@@H]1CN(C[C@@H]1c2cnc3cnc4[nH]ccc4n23)C(=O)NCC(F)(F)F
  • Mol. Mass: 380.37
  • ALogP: 2.91
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)



United States

$119.5420 - $171.4803
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

abt-494 | upadacitinib | upadacitinib tartrate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue